Mergers & Acquisitions ·
Zymeworks Inc. entered into a merger agreement with Theravance Biopharma, Inc. to acquire it as a wholly owned…
ZYMEZymeworks Inc.
Zymeworks Inc. entered into a merger agreement with Theravance Biopharma, Inc. to acquire it as a wholly owned subsidiary. Shareholders of Theravance will receive $17.00 in cash per share and one contingent value right (CVR) per share. The transaction is expected to close in the second half of 2026 and is being financed through a combination of cash on hand and $350 million in senior secured notes. Zymeworks is a biotechnology company focused on developing biopharmaceutical products.